– Daewoong Pharmaceutical: “En espera de la aprobación sin contratiempos tras el exitoso ensayo clínico de fase 3 en China, con el objetivo de llegar a 100 países para 2027” SEÚL, Corea del Sur, 30 de julio de 2023 /PRNewswire/ — Fexuprazan es el medicamento número 34 de producción…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.